Content area
Full Text
On its way to developing a universal flu vaccine, University of Oxford spinout Vaccitech has raised £20 million ($27 million) in series A financing, backed by Alphabet’s venture capital arm GV (formerly Google Ventures), Sequoia China and Oxford Sciences Innovation.
The £20 million, together with the £10 million seed round Vaccitech nabbed in 2016, will support development of the company’s lead vaccine candidate, which is designed to protect against all strains of influenza A virus. The company is also working on a cancer vaccine, with a phase 2 study expected to start early this year.
Traditional flu vaccines target antigens on the surface of...